home / stock / imrx / imrx news

IMRX News and Press, Immuneering Corporation From 04/19/23

Stock Information
Company Name: Immuneering Corporation
Stock Symbol: IMRX
Market: NASDAQ
Website: immuneering.com
Menu
IMRX IMRX Quote IMRX Short IMRX News IMRX Articles IMRX Message Board
Get IMRX Alerts

News, Short Squeeze, Breakout and More Instantly...
IMRX - Immuneering gains as Morgan Stanley, Mizuho upgrade on lead asset

2023-04-19 08:17:22 ET Shares of Immuneering Corporation ( NASDAQ: IMRX ) added ~8% pre-market Wednesday after Morgan Stanley and Mizuho upgraded the clinical-stage oncology company citing initial data for its lead candidate IMM-1-104. At the annual meeting of the American A...
IMRX - Immuneering Announces $30 Million Underwritten Offering

CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX) (“Immuneering”), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced the pr...

IMRX - Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline

Data presented at AACR Annual Meeting support IMM-1-104's potential to address a broad population of patients with RAS mutant tumors IMM-1-104 well tolerated with no dose limiting toxicities (DLTs) or serious adverse events (SAEs) observed First demonstration of novel deep cyclic ...

IMRX - Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the ...
IMRX - Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023

CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that it will hold a virtual Investor...

IMRX - Immuneering Appoints Harold E. Brakewood as Chief Business Officer

CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, announced today that it has appointed Harold E. Brak...

IMRX - Why Shares of Immuneering Jumped This Week

2023-03-24 13:25:08 ET Shares of Immuneering (NASDAQ: IMRX) were up 23.7% for the week as of early Friday afternoon, according to data provided by S&P Global Market Intelligence . The healthcare stock closed at $8.07 a share last Friday before rising to as high as $11.08...
IMRX - Ocean Biomedical, Avenue top healthcare gainers; InVivo, Akebia lead losers' pack

2023-03-09 10:01:05 ET Gainers: Ocean Biomedical OCEA +57% . Avenue Therapeutics ( ATXI ) +21% . Unicycive Therapeutics ( UNCY ) +19% . Assertio ( ASRT ) +12% . Immuneering ( IMRX ) +11% . Losers: InVivo Therapeutics NVIV ...

IMRX - AVAH, IMRX and SFR among mid-day movers

2023-03-08 12:54:43 ET Gainers: Kimball International ( KBAL ) +83% . Arlo Technologies ( ARLO ) +45% . Diversey ( DSEY ) +37% . Maxeon ( MAXN ) +32% . LifeStance ( LFST ) +26% . Mesoblast ( MESO ) +26% . Vertex (...

IMRX - Immuneering Corporation (IMRX) Q4 2022 Earnings Call Transcript

2023-03-06 22:50:05 ET Immuneering Corporation (IMRX) Q4 2022 Earnings Conference Call March 6, 2023 4:30 PM ET Company Participants Laurence Watts - Investor Relations, Gilmartin Group Benjamin Zeskind - President and Chief Executive Officer Brett Hall - Chief S...
Previous 10 Next 10